Patents by Inventor Craig Rosen
Craig Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130253979Abstract: A computer implemented method for managing risk, which can include determining an organizational impact score from an aggregate of scenario impact scores and storing the organizational impact score in a memory of the computer. Some embodiments include calculating a likelihood score based upon an analysis of threats, imminence of each threat, and a likelihood associated with each threat, and storing the likelihood score in a memory of the computer. In some embodiments, an organizational maturity score is determined based on the ability of the organization to mitigate the actions of a potential threat and recover from a given scenario, and the organizational maturity score is stored in a memory of the computer. Some embodiments include calculating a Risk Index using a processor of the computer wherein the Risk Index equals the impact score multiplied by the likelihood score and divided by the maturity score.Type: ApplicationFiled: March 13, 2013Publication date: September 26, 2013Applicant: Pacific Gas and Electric CompanyInventors: Ramsey Williams, James Sample, Craig Rosen, Suneel Sundar, Richard Jones, Eddie Borrero
-
Patent number: 8524869Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).Type: GrantFiled: March 22, 2010Date of Patent: September 3, 2013Assignee: Teva Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
-
Patent number: 8513189Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: April 1, 2011Date of Patent: August 20, 2013Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20130203164Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions (such as immune, cardiovascular, cancer, and other proliferative diseases, disorders, and/or conditions) related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.Type: ApplicationFiled: March 22, 2013Publication date: August 8, 2013Applicant: Human Genome Sciences, Inc.Inventors: Craig A. ROSEN, Steven M. Ruben
-
Publication number: 20130157933Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.Type: ApplicationFiled: April 1, 2011Publication date: June 20, 2013Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20130150296Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: April 1, 2011Publication date: June 13, 2013Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20130102533Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: September 12, 2012Publication date: April 25, 2013Inventors: Craig A. Rosen, William A. Haseltine
-
Patent number: 8410248Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions (such as immune, cardiovascular, cancer, and other proliferative diseases, disorders, and/or conditions) related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.Type: GrantFiled: April 2, 2010Date of Patent: April 2, 2013Assignee: Human Genome Sciences Inc.Inventors: Craig A. Rosen, Steven M. Ruben
-
Publication number: 20130029911Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: September 12, 2012Publication date: January 31, 2013Inventors: Craig A. Rosen, William A. Haseltine
-
Patent number: 8334365Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: June 7, 2007Date of Patent: December 18, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, David W. LaFleur
-
Patent number: 8329179Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.Type: GrantFiled: January 18, 2008Date of Patent: December 11, 2012Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
-
Publication number: 20120308480Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Patent number: 8287859Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: June 3, 2010Date of Patent: October 16, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, David LaFleur
-
Patent number: 8263743Abstract: Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: GrantFiled: November 13, 2008Date of Patent: September 11, 2012Assignee: Teva Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Patent number: 8252739Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: April 1, 2011Date of Patent: August 28, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20120213777Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: April 30, 2012Publication date: August 23, 2012Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 8216569Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: October 31, 2007Date of Patent: July 10, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 8211439Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: October 30, 2007Date of Patent: July 3, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben, Olivier Blondel
-
Patent number: 8206708Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: April 28, 2011Date of Patent: June 26, 2012Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Publication number: 20120122762Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: ApplicationFiled: January 26, 2012Publication date: May 17, 2012Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, Daniel R. Soppet, Kenneth C. Carter, Daniel P. Bednarik, Gregory A. Endress, Guo-Liang Yu, Jian Ni, Ping Feng, Paul E. Young, John M. Greene, Ann M. Ferrie, D. Roxanne Duan, Jing-Shan Hu, Kimberly A. Florence, Henrik S. Olsen, Carrie L. Fischer, Reinhard Ebner, Laurie A. Brewer, Paul A. Moore, Yanggu Shi, David W. LaFleur, Yi Li, Zhizhen Zeng, Hla Kyaw